Nevertheless, according to a data analysis by Drug Channels,2 the net prices of brand-name drugs, on average, dropped 3% in 2023, decreasing for a sixth consecutive year. If a maximum fair price is agreed upon by both sides, those new prices will take effect in Medicare in 2026. Manufacturers, themselves, are increasingly getting involved in the DTC mix and expanding such service offerings into new territories. "We haven't seen that offered with a lot of other drugs," Jesse Mendelsohn, senior vice president, Model N, tells Pharm Exec. "My guess is Lilly has some interesting regulatory hurdles that it's going to have to overcome to do this.

Source: Wall Street Journal February 12, 2024 15:09 UTC